Additionally, the development of predictive tools and biomarkers that can guide treatment selection and adjustment is seen as a promising area for enhancing personalized care
Clearly, Hims is making a shit load of money selling compounded semaglutide
What this means for overall gut health overall gut health Potential positives: Less glycemic volatility (fewer glucose-driven GI symptoms in some with diabetes) Reduced reflux triggers for some if weight loss decreases intra-abdominal pressure Improved MASLD/MASH biomarkers via weight loss and metabolic effects Lower overall intake may calm visceral hypersensitivity in some IBS-D cases Potential challenges: Delayed emptying early fullness, nausea, reflux, or vomiting if portions/fats are too high Constipation in those with slow motility or low fiber/fluid intake Gallstones with rapid loss Undernutrition may contribute to overall symptoms and inflammation impacting the gut Poor balance of meals due to low intake may negatively impact the gut microbiome Rare but serious pancreatitis or ileus requiring immediate care The bottom line is that these medications arent 100% good or 100% bad
Unknown Drug Interactions : BPC-157's activity on nitric oxide pathways and growth hormone receptors raises unresolved concerns about interactions with medications (NSAIDs, anticoagulants, and hormonal therapies)
Cagrilintide is a next-generation investigational peptide that functions as a long-acting amylin receptor agonist
Two panelists covered recent findings related to how GLP-1 agonists produce adverse side effects such as vomiting and thirst suppression, while the other two talked about new approaches in GLP-1 therapies
